# Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

> **NCT02132234** · PHASE4 · UNKNOWN · sponsor: **Jagiellonian University** · enrollment: 100 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Hypertension

## Interventions

- **DRUG:** Etanercept
- **DRUG:** Adalimumab
- **DRUG:** Certolizumab
- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT02132234
- **Lead sponsor:** Jagiellonian University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-06
- **Primary completion:** 2014-07
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2014-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02132234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02132234, "Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02132234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*